XML 31 R10.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Acquisitions | 12 Months Ended
--- | ---
Dec. 31, 2023
Acquisitions [Abstract] |
ACQUISITIONS | NOTE 3 – ACQUISITIONS On October 24, 2023, the Company acquired 100% of the issued and outstanding preferred and common stock of Healthy Offers, Inc., a Nevada corporation d/b/a Medicx Health. Medicx Health is a healthcare consumer-focused omnichannel marketing and analytics company. The acquisition of Medicx Health is expected to enhance and expand the Company’s technology offerings, providing additional opportunities for revenue growth. The acquisition date fair value of consideration transferred was calculated as follows:
Net cash transferred |  | $ | 83,888,239 |
Fair value of common stock transferred |  |  | 12,091,142 |
Fair value of consideration transferred |  | $ | 95,979,381 |
The goodwill balance reflects the benefits associated with future iterations of the technology platforms, new customer relationships anticipated as a result of the transaction and market participant synergies from economies of scale and is not deductible for tax purposes. In addition, the Company is required to remit, upon collection from the appropriate authorities, approximately $1.0 million related to certain state and federal income tax receivables which were included on Medicx Health’s balance sheet at the date of acquisition. The Company has recorded $1.0 million in Taxes receivable, to reflect the receivables due to the Company and $1.0 million in Accrued expenses, to reflect the total amount due to the former stockholders of Medicx Health. The following table summarizes the estimated fair value of assets acquired and liabilities assumed at the acquisition date:
Assets Acquired |  |  |
Cash |  | $ | 940,974 |
Accounts receivable |  |  | 6,028,048 |
Taxes receivable |  |  | 1,035,754 |
Prepaid expenses and other |  |  | 912,719 |
Property and equipment |  |  | 33,476 |
Customer relationships intangible |  |  | 34,000,000 |
Trademark and patent intangible |  |  | 5,700,000 |
Technology intangibles |  |  | 8,300,000 |
Operating lease right-of-use assets |  |  | 145,075 |
Deposits |  |  | 9,727 |
|  |  | 57,105,773 |
Liabilities Assumed |  |  |  |
Accounts payable |  |  | 1,997,348 |
Accrued expenses |  |  | 3,848,403 |
Lease liabilities |  |  | 166,098 |
Deferred revenue |  |  | 75,003 |
Deferred tax liabilities |  |  | 12,032,798 |
|  |  | 18,119,650 |
Net assets acquired |  |  | 38,986,123 |
Goodwill |  |  | 56,993,258 |
Fair value of consideration transferred |  | $ | 95,979,381 |
The Company used a third-party valuation specialist to value the intangible assets acquired. The identifiable intangibles are being amortized on a straight line basis over the following estimated useful lives:
Customer relationship intangible |  | 15 years
Trademark and patent intangible |  | 10 years
Technology intangibles |  | 4 to 10 years
The Company recognized $4.3 million of acquisition related costs that were expensed in the current period. These costs are included in the consolidated statement of operations in the line item entitled “Other sales, general and administrative expenses.” The results of operations of Medicx Health have been included in the consolidated statement of operations since the date of acquisition. The amounts of revenue and net income of Medicx Health included in the Company’s consolidated statement of operations for the period from the acquisition date until December 31, 2023, are as follows:
Revenue |  | $ | 4,546,497 |
Net income |  |  | 314,082 |
The following represents the pro-forma consolidated statement of operations as if Medicx Health had been included in the consolidated results of the Company for the full years ended December 31, 2023, and 2022:
|  | Year ended December 31, 2022 |
Pro-forma consolidated statement of operations |  | 2023 |  |  | 2022 |
Revenue |  | $ | 97,066,241 |  |  | $ | 90,521,236 |
Net loss |  |  | (18,616,303 | ) |  |  | (16,157,521 | )
These amounts have been calculated after applying the Company’s accounting policies, adjusting Medicx Health results to reflect the additional amortization that would have been charged assuming the fair value adjustments to intangible assets had been applied on January 1, 2022, full year interest expense associated with the term loan and elimination of interest income on short-term investments that were used to fund the acquisition, one time transaction related items, including the amounts incurred by the Company, discussed above and $9.6 million in transaction related expenses incurred by Medicx Health. On April 14, 2022, we completed the acquisition of substantially all of the assets of EvinceMed Corp., a privately held leading provider of delivering end-to-end automation for specialty pharmaceutical transactions. We completed the acquisition to expand the breadth of the solutions we offer our customers, particularly where specialty medications are involved, The acquisition included the full Market Access Management Platform for supporting pharma manufacturers, hub providers and pharmacies to improve patient access, speed to therapy and activation of affordability programs. The consideration was comprised of $2.0 million in cash, the issuance of 240,741 shares of common stock valued at $9,374,455, and $708,334 of amounts previously paid. The total purchase price was $12,082,789. Of the 240,741 shares of common stock, 185,185 were issued at closing and 55,556 were issued but held back to secure potential adjustments to the purchase price that may result from the indemnification obligations of and the EvinceMed shareholder indemnitors. The holdback amount will be released twelve months from the closing, subject to any adjustments for the payment by EvinceMed and the shareholder indemnitors for its and their indemnification obligations. The purchase price was allocated to acquired technology totaling $4,149,000 with an estimated useful life of 8 years and the remaining $7,933,789 was allocated to goodwill. Goodwill represents the processes and synergies expected by integrating those processes with our own. The full amount of goodwill will be deductible for tax purposes using a 15 year life. The increase in goodwill for the period is fully accounted for by this acquisition. We determined pro forma data was immaterial for financial reporting purposes. Acquisition costs of approximately $19,739 were expensed as incurred.

X
- References No definition available. + Details
Name: | us-gaap_AssetAcquisitionAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for asset acquisition. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3 + Details
Name: | us-gaap_AssetAcquisitionTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration